Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966· Phase 1/2· Daiichi Sankyo· Source
Recruiting
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940· Phase 3· SWOG Cancer Research Network· Source
Contact: Raymond C. Wadlow (principal investigator)
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source
Contact: Stephanie Van Bebber
Recruiting
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06769698· Phase 2· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07166406· Phase 3· NRG Oncology· Source
Contact: Grace Lee (principal investigator)
Recruiting
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
NCT07335224· Inova Health Care Services· Source
Contact: Tuyetson Nguyen, MPH
Recruiting
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT07104565· Phase 2· Incyte Corporation· Source
Recruiting
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
NCT07195591· Phase 3· GT Medical Technologies, Inc.· Source
Contact: Kevin Choe, MD, PhD
Active, not recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source
Contact: Leslie M. Randall (principal investigator)
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· NRG Oncology· Source
Contact: Tobias R. Chapman (principal investigator)
Active, not recruiting
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT06995898· National Cancer Institute (NCI)· Source
Contact: Rebecca D. Kaltman (principal investigator)
Recruiting
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT06500481· Phase 3· NRG Oncology· Source
Contact: Avani D. Rao (principal investigator)
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Genmab· Source
Active, not recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· Phase 3· NovoCure GmbH· Source
Active, not recruiting
Activity Coaching During Pelvic Radiation Therapy
NCT06746428· Inova Health Care Services· Source
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· Phase 2· National Cancer Institute (NCI)· Source
Contact: Danielle A. Shafer (principal investigator)
Active, not recruiting
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393· Phase 2· National Cancer Institute (NCI)· Source
Contact: Danielle A. Shafer (principal investigator)
Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Recruiting
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306· Phase 1/2· Bristol-Myers Squibb· Source
Contact: Sheinei Alan, Site 0013
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357· Phase 1/2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· Phase 2· National Cancer Institute (NCI)· Source
Contact: Danielle A. Shafer (principal investigator)
Recruiting
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381· Phase 3· GOG Foundation· Source
Contact: Adela Mahmutovic
Active, not recruiting
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
NCT06106308· Phase 2· Cardiff Oncology· Source
Active, not recruiting
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706· Phase 1· Pliant Therapeutics, Inc.· Source
Contact: Pliant Therapeutics Medical Monitor
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304· Phase 1· Erasca, Inc.· Source
Recruiting
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
NCT06007846· Phase 2/3· Inova Health Care Services· Source
Contact: Elahe Mollapour
Active, not recruiting
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823· Phase 2· Taiho Oncology, Inc.· Source
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Melissa Yacur (principal investigator)
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519· Phase 3· Nuvation Bio Inc.· Source
Contact: Stephanie Van Bebber
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377· Phase 2· National Cancer Institute (NCI)· Source
Contact: Timothy L. Cannon (principal investigator)
Active, not recruiting
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
NCT03862430· Phase 2· NuvOx LLC· Source
Recruiting
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686· Phase 2· NRG Oncology· Source
Contact: Daniel W. Kim (principal investigator)
Recruiting
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Arthur A. Winer (principal investigator)
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562· Phase 3· Jazz Pharmaceuticals· Source
Contact: Clinical Trial Disclosure & Transparency
Active, not recruiting
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Recruiting
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196· Phase 2· National Cancer Institute (NCI)· Source
Contact: Sekwon Jang (principal investigator)
Active, not recruiting
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212· Phase 3· NRG Oncology· Source
Recruiting
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
NCT05431088· Phase 2/3· Pfizer· Source
Active, not recruiting
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290· Phase 1/2· Black Diamond Therapeutics, Inc.· Source
Active, not recruiting
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376· Phase 3· NRG Oncology· Source
Active, not recruiting
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
NCT04729959· Phase 2· National Cancer Institute (NCI)· Source
Showing 50 of 96.